Engagement of the T cell receptor against an oncolytic virus generates a population of hypereffector CAR T cells with potent antitumor activity 2256915
Abstract Introduction We have shown that combining CAR T cells with oncolytic viruses (OVs) generates a subpopulation of highly cytotoxic CAR T cells that can mediate long-term solid tumor therapy. Methods To profile these CAR T cells, we used C57BL/6 mice bearing B16F10 tumors expressing EGFRviii, treated with anti-EGFRviii CAR T cells and the OV vesicular stomatitis virus (VSV). TCR signaling in CAR T cells was investigated using the novel Tocky transgenic mouse model, which reports T cell activation over time using an unstable fluorescent protein reporter of Nr4a3. We further investigated CAR T phenotypes using CyTOF and scRNA-Seq. Results Using an MHC I tetramer for the dominant VSV epitope VSV N52-59, we found that 20-50% of transfused CAR T adopted TCR specificity against VSV N (referred to as TCR-primed), indicating significant in vivo expansion. Ex vivo, these TCR-primed CAR T produced increased levels of granzyme B and IFNγ over tetramer-negative CAR T against either TCR or CAR targets. However, TCR-primed CAR T cells were notably less activated via Nr4a3 as compared to non-TCR-primed CAR T. CyTOF and scRNA-Seq analyses demonstrated a hypereffector phenotype among TCR-primed CAR, with increased expression of T-bet, CD44, granzyme B, IFNγ, and perforin. TCR sequencing revealed hyperexpansion of VSV N-specific CAR T cells and little overlap in clonotypes between CAR T co-treated with PBS versus VSV. These TCR-primed CAR T cells exhibited a CD4-helped phenotype with increased expression of chemotactic and migratory transcripts. When CAR T and OV were administered with antibody-mediated CD4 depletion, the TCR-primed CAR population was significantly diminished, emphasizing the importance of the immune triad for CAR T expansion. Conclusion Overall, CAR T cells that undergo endogenous anti-viral TCR priming and signaling adopt a unique phenotype that promotes their expansion and cytotoxic function. Interactions with CD4 T cells appear to be integral for the generation of this subpopulation of CD8 CAR T cells. Funding Source NIH Topic Categories Tumor Immunology: Checkpoints, Prevention, and Treatment (TIPT)
Authors
- Jill Thompson
- Elizabeth Appleton
- Laura Evgin (ORCID: https://orcid.org/0000-0002-0913-5038)
- Olivia Liseth (ORCID: https://orcid.org/0000-0001-8916-0470)
- Benjamin Kendall (ORCID: https://orcid.org/0000-0002-7002-7474)
- Masahiro Ono (ORCID: https://orcid.org/0000-0002-9284-7326)
- Richard Vile
- Alan Melcher (ORCID: https://orcid.org/0000-0002-2042-3380)
Institutions
- University of British Columbia (CA)
- WinnMed (US)
- Institute of Cancer Research (CA)
- Mayo Clinic in Arizona (US)
- Imperial College London (GB)
Publication Details
- Journal
- The Journal of Immunology
- Published
- 2026-07-28
- DOI
- https://doi.org/10.1093/jimmun/vkag141.373
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.00